Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

@article{Schmidt2008PreclinicalCO,
  title={Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia},
  author={CJ Schmidt and D. S. Chapin and Julie Cianfrogna and M Corman and Mih{\'a}ly Haj{\'o}s and J F Harms and William E. Hoffman and L. Lebel and S A McCarthy and Frederick R. Nelson and Caroline Proulx-Lafrance and M J Majchrzak and A D Ramirez and Kevin Schmidt and Patricia A. Seymour and J. A. Siuciak and F. David Tingley and R. Dorrington Williams and P Verhoest and Frank S. Menniti},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2008},
  volume={325},
  pages={681 - 690}
}
We have recently proposed the hypothesis that inhibition of the cyclic nucleotide phosphodiesterase (PDE) 10A may represent a new pharmacological approach to the treatment of schizophrenia (Curr Opin Invest Drug 8:54–59, 2007). PDE10A is highly expressed in the medium spiny neurons of the mammalian striatum (Brain Res 985:113–126, 2003; J Histochem Cytochem 54:1205–1213, 2006; Neuroscience 139:597–607, 2006), where the enzyme is hypothesized to regulate both cAMP and cGMP signaling cascades to… Expand
The Role of Phosphodiesterases in Schizophrenia
TLDR
A brief overview of recent studies implicating PDE inhibition, focusing on PDE4 and PDE10, as targets for treating the positive, negative or cognitive symptoms associated with schizophrenia is provided. Expand
Small-molecule phosphodiesterase probes: discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1
TLDR
This work has used high-throughput screening, structure-based design, and targeted synthetic chemistry to discover the 4-aminoquinazoline-based PDE1-selective inhibitors, each of which are Pde1 inhibitors that readily cross the blood brain barrier. Expand
Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile
TLDR
The findings suggest that FRM-6308 has the adequate pharmacological profile to advance testing in clinical trials and demonstrate antipsychotic efficacy of PDE10A inhibition for the treatment of schizophrenia patients. Expand
Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment.
TLDR
The profiling of PDE10A chemical biology probes described herein illustrates a strategy by which high affinity inhibitors can be converted into probes for determining selectivity and target engagement of drug candidates in complex biological matrices from native sources. Expand
Phosphodiesterase 10 inhibitors in clinical development for CNS disorders
TLDR
The underlying biological rationale of PDE10 as a target in schizophrenia, Parkinson's and Huntington’s disease is reviewed based on peer-reviewed published articles, the status of the different PDE 10–I in clinical development for various CNS indications is explored and possible reasons for the clinical trial failures and translational disconnect are explored. Expand
Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present)
TLDR
PDE2A is a dual substrate enzyme and is expressed in both the periphery and in the central nervous system, however its expression is highest in the brain, which suggests that this enzyme may regulate intraneuronal cGMP and cAMP levels in brain areas involved in emotion, perception, concentration, learning and memory. Expand
Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition
TLDR
It is demonstrated that SEP-39 is a potent, orally active PDE10A inhibitor with therapeutic potential in a number of psychiatric indications and appears to require less PDE 10A inhibition than the reversal of PCP-induced hyperlocomotion or EEG effects. Expand
A Novel Phosphodiesterase 1 Inhibitor DSR-141562 Exhibits Efficacies in Animal Models for Positive, Negative, and Cognitive Symptoms Associated with Schizophrenia
TLDR
This is the first paper showing that a phosphodiesterase 1 inhibitor is efficacious in animal models for positive and negative symptoms associated with schizophrenia and it is suggested that DSR-141562 is a therapeutic candidate for positive, negative, and cognitive symptoms in schizophrenia. Expand
Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease
TLDR
The action of phosphodiesterase inhibitors and their role as therapeutic agents in HD are discussed. Expand
Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications
TLDR
The behavioral effects of the selective PDE10A inhibitor MP-10 are compared to those of the clinical standard D₂ antagonist risperidone in rhesus monkeys using a standardized motor disability scale for parkinsonian primates and a newly designed "Drug Effects on Nervous System" scale to assess non-motor effects. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
TLDR
By enhancing corticostriatal signaling, PDE10A inhibitors have the potential to improve some of the cognitive symptoms of schizophrenia and are consistent with their potential as antipsychotic agents. Expand
Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis
TLDR
The results indicate that PDE10A regulates the activation of striatal medium spiny neurons through effects on cAMP- and cGMP-dependent signaling cascades and demonstrate that papaverine has efficacy in behavioral models predictive of antipsychotic activity. Expand
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
TLDR
The studies indicate that PDE 10A is associated with post-synaptic membranes of the medium spiny neurons, suggesting that the specialized compartmentation of PDE10A enables the regulation of intracellular signaling from glutamatergic and dopaminergic inputs to these neurons. Expand
Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function
TLDR
The findings suggest that PDE10A is involved in regulating striatal output, possibly by reducing the sensitivity of medium spiny neurons to glutamatergic excitation, and presents a novel treatment for psychosis. Expand
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
TLDR
The data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia. Expand
Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian Species
TLDR
It is demonstrated that PDE10A is an evolutionarily conserved phosphodiesterase highly expressed in the brain but with restricted distribution in the periphery in multiple mammalian species. Expand
Immunohistochemical localization of PDE10A in the rat brain
TLDR
Data suggest a role for PDE10A in regulating activity within both the striatonigral and striatopallidal pathways, and a second, distinct function for the enzyme in these regions. Expand
The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia
TLDR
To support the contention that NMDA receptor antagonist administration represents a viable model of schizophrenia, the behavioral and neurobiological effects of these drugs are discussed, especially with regard to differing profiles following single-dose and long-term exposure. Expand
Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat
TLDR
It is found that ketamine decreased Glu and DA levels, as well as HIAA/5-HT turnover, and that LY379268 could prevent ketamine effects on Glu level but not on monoamine transmission, which may indicate that the inability of Ly379268 to reverse PPI deficits is attributable to its lack of effect on ketamine-induced changes in monoamine Transmission. Expand
Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.
TLDR
It is proposed that schizophrenia is associated with strongly interconnected abnormalities of GLU and DA transmission: NMDA hypofunction in the PFC and its connections might generate a pattern of dysregulation of DA systems that, in turn, further weakens NMDA-mediated connectivity and plasticity. Expand
...
1
2
3
4
5
...